- Ongoing, recruitingTherapeutic confirmatory (Phase III)
INTEGRATE IIb A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
This study is testing two medicines, regorafenib and nivolumab, against standard chemotherapy for advanced stomach or gullet cancer that hasn't responded to previous treatments. Researchers want to see if this new combination helps people live longer.
For: refractory · advanced gastro-oesophageal cancerAustria · Germany · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of systemic therapy with regorafenib and pembrolizumab, versus locoregional therapy with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria (REPLACE).
This study looks at new ways to treat a type of liver cancer that has spread. It compares two treatments: one using regorafenib and pembrolizumab given through the body, and another using targeted treatments like TACE or TARE directly in the liver. The main goal is to see which treatment works best to stop the cancer from growing.
For: Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria.Belgium · Spain · Italy